Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Increase in Short Interest

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a significant growth in short interest in December. As of December 15th, there was short interest totaling 98,252 shares, a growth of 648.8% from the November 30th total of 13,122 shares. Based on an average trading volume of 108,651 shares, the short-interest ratio is presently 0.9 days. Approximately 5.9% of the company’s shares are short sold. Approximately 5.9% of the company’s shares are short sold. Based on an average trading volume of 108,651 shares, the short-interest ratio is presently 0.9 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. O Brien Greene & Co. Inc bought a new position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 60,000 shares of the company’s stock, valued at approximately $31,000. O Brien Greene & Co. Inc owned approximately 0.20% of Acurx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 11.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wall Street Zen lowered shares of Acurx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Acurx Pharmaceuticals in a research report on Tuesday, September 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Performance

Acurx Pharmaceuticals stock traded down $0.08 during mid-day trading on Wednesday, hitting $3.42. 11,914 shares of the company traded hands, compared to its average volume of 246,619. Acurx Pharmaceuticals has a one year low of $3.17 and a one year high of $25.00. The stock has a market cap of $7.16 million, a price-to-earnings ratio of -0.40 and a beta of -1.25. The stock has a fifty day moving average price of $4.72 and a 200-day moving average price of $6.03.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($1.23) EPS for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.38. Sell-side analysts predict that Acurx Pharmaceuticals will post -0.89 EPS for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical?stage biopharmaceutical company focused on the discovery and development of novel anti?infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).